RM-1-Luc Cells

RM-1-Luc is a bioluminescent derivative of the murine RM-1 prostate carcinoma cell line, engineered to stably express a firefly luciferase reporter gene. The parental RM-1 cell line was established from a carcinoma of the mouse prostate gland derived from fetal C57BL/6 tissue at 17 fetal days and is a rapidly growing, androgen-independent prostate cancer model in the C57BL/6 syngeneic background. RM-1 cells exhibit epithelial morphology, express typical prostate carcinoma markers, and form aggressive tumors in immunocompetent C57BL/6 hosts, making this model suitable for studying tumor-immune interactions and evaluating immunotherapy strategies against prostate cancer.

The stable luciferase integration in RM-1-Luc enables sensitive, noninvasive bioluminescence imaging (BLI) of primary tumor growth and metastatic dissemination in living C57BL/6 mice following luciferin administration. The emitted signal correlates with viable tumor cell number, supporting longitudinal assessment of tumor engraftment, growth kinetics, and therapeutic response without repeated invasive procedures. RM-1-Luc is particularly valuable for preclinical evaluation of checkpoint inhibitors, androgen-deprivation strategies, and combination immunotherapy approaches in an immunocompetent prostate cancer model.

RM-1-Luc retains the key biological features of the parental RM-1 line, including its androgen-independent growth, C57BL/6 syngeneic compatibility, and established use in prostate cancer research. The luciferase reporter enhances experimental sensitivity and enables real-time pharmacodynamic assessment. Researchers should validate luciferase activity, growth kinetics, and immunological phenotype under their specific experimental conditions prior to large-scale in vivo use.